<p> Mays Cancer Center at UT Health San Antonio melanoma expert Monte Shaheen, MD, was part of a team of investigators that conducted a phase II clinical trial funded by the National Cancer Institute (NCI) to determine the efficacy and safety of administering the immunotherapy drug pembrolizumab before and after surgery in high-risk melanoma patients. […]</p>
Share This Story
<p> Amelie Ramirez, DrPH, MPH, leader of Salud America! at UT Health San Antonio, is among 15 new inductees to the San Antonio Women’s Hall of Fame. The San Antonio Women’s Hall of Fame has annually inducted women from Bexar and surrounding counties who have shaped the future of San Antonio and paved the way for women […]</p>
Share This Story
<p>The University of Texas Health Science Center San Antonio was mentioned in this story. Read More</p>
Share This Story
<p>The University of Texas Health Science Center San Antonio was mentioned in this story. Read More</p>
Share This Story
<p>The University of Texas Health Science Center San Antonio was mentioned in this story. Read More</p>
Share This Story
<p>The University of Texas Health Science Center was mentioned in this story. Read More</p>
Share This Story
<p>Randy Wright, MD, Medicine/Gastroenterology, was interviewed for this news segment. Watch Now</p>
Share This Story
<p>Two health care leaders have been appointed to executive roles for the UT Health San Antonio Multispecialty and Research Hospital. The new hospital, currently under construction, will offer leading cancer treatment and specialties including neurosciences, orthopaedics, urology, thoracic surgery and bariatrics to residents of South Texas. Jeremy Viles, DNP, MBA, RN, NE-BC, was appointed as […]</p>
Share This Story
<p>Anton Fries, MD, PhD, chief, Division of Plastic and Reconstructive Surgery, was interviewed for this news segment. Watch Now</p>
Share This Story
<p>The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the […]</p>
Share This Story